Chameditech Launches Hyaluronic Acid Filler in Turkey... Accelerates Entry into Europe

[Asia Economy Reporter Cho Hyun-ui] Cha Meditech, a subsidiary of Cha Biotech, is strengthening its product line of the hyaluronic acid (HA) filler 'Hiafillia' developed in-house to enter the overseas filler market.

On the 30th, Cha Meditech announced, "We have newly organized a lineup of four types of Hiafillia fillers tailored for the European, Russian, and Middle Eastern markets, and recently launched the products in the local market through a Turkish distributor of aesthetic and plastic surgery medical devices." The Turkish aesthetic plastic surgery market ranked 8th worldwide as of 2018, making it a noteworthy market.

With the recent acquisition of European certification (CE) in Turkey, Cha Meditech plans to officially enter the European market. This is because product launches in other European countries have become possible without separate procedures or with simplified procedures.

Cha Meditech stated, "We plan to expand the market to 15 European countries, including Spain and the United Kingdom, where contract discussions were already underway."

Next month, Hiafillia S, M, V, and I will be launched in Russia, and the market will also be expanded to the Middle East. Hiafillia S, M, V, and I are customized fillers developed with a focus on volume enhancement effects. Their physical properties and safety have been significantly improved compared to existing products.

Kim Seok-jin, CEO of Cha Meditech, said, "Starting with the launch in Turkey, we will continuously discover local partners in the European, Russian, and Middle Eastern markets," adding, "We will expand Hiafillia's market share based on excellent product quality and technological capabilities."